Psoriasis Vulgaris Exacerbation during Treatment with a PD-1 Checkpoint Inhibitor: Case Report and Literature Review
Objective: The incidence of immune-related adverse events is growing as the use of checkpoint inhibitors is exponentially increasing. Cutaneous adverse events are among the most frequent immune-related adverse events. The purpose of this case report and literature review is to highlight psoriasis as...
Saved in:
Main Authors: | Marlies De Bock (Author), Eva Hulstaert (Author), Vibeke Kruse (Author), Lieve Brochez (Author) |
---|---|
Format: | Book |
Published: |
Karger Publishers,
2018-08-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Psoriasis de novo or exacerbation by PD-1 checkpoint inhibitors
by: Zi Wan, et al.
Published: (2024) -
Exacerbation of pre‐existence psoriasis following immune checkpoint inhibitor treatment
by: Yoko Minokawa, et al.
Published: (2022) -
PD-1/PD-L1 Checkpoint Inhibitors in Tumor Immunotherapy
by: Jinhua Liu, et al.
Published: (2021) -
PD-1/PD-L1 immune checkpoint inhibitors in glioblastoma: clinical studies, challenges and potential
by: Tianrui Yang, et al.
Published: (2021) -
Immune checkpoint inhibitor‐mediated psoriasis treated with biologics
by: Pei Ming Yeo, et al.
Published: (2023)